Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > BIND Doses First Patient in a Phase 2 Clinical Study of BIND-014 in Prostate Cancer: Second of Two Phase 2 Clinical Studies Initiated with BIND-014 in 2013

Abstract:
BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that it has dosed the first patient in a Phase 2 clinical trial to assess the safety and efficacy of BIND-014, a PSMA-targeted Accurin containing docetaxel, as first-line therapy in patients with chemotherapy naïve metastatic castrate-resistant prostate cancer.

BIND Doses First Patient in a Phase 2 Clinical Study of BIND-014 in Prostate Cancer: Second of Two Phase 2 Clinical Studies Initiated with BIND-014 in 2013

Cambridge, MA | Posted on August 19th, 2013

"While treatment options for metastatic castrate-resistant prostate cancer have advanced in recent years, primarily due to an increased understanding of androgen receptor biology, a significant unmet need remains for patients who fail hormonal agents," said Gregory Berk, MD, Chief Medical Officer of BIND Therapeutics. "We are pleased our Phase 1 trial of BIND-014 established the safety profile and appropriate Phase 2 dose, and we are advancing BIND-014 in clinical development to further evaluate it as a potential treatment option for patients who are in need of more effective therapies."

"Prostate-specific membrane antigen (PSMA) is an attractive target in patients with advanced prostate cancer. By delivering an established cytotoxic to this target, there is the potential to significantly improve the therapeutic index and patient outcomes," commented Howard Scher, MD, the Chief of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at the Weill Cornell Medical College, and principal investigator of the study.

This 40 patient, open label, single arm multi-center study is designed to determine the efficacy of BIND-014 as measured by progression-free survival in patients with chemotherapy-naïve metastatic castrate-resistant prostate cancer. For more specific information on the trial, including patient eligibility and clinical trial endpoints, please visit www.clinicaltrials.gov (NCT01812746).

BIND-014 represents the first Accurin nanomedicine to reach the clinic from BIND's Medicinal Nanoengineering® platform. BIND-014 targets PSMA, a target expressed on prostate cancer cells and the blood vessels of many types of non-prostate solid tumors, and contains docetaxel, a clinically-validated and widely used chemotherapy drug. Docetaxel is currently FDA-approved for the treatment of breast cancer, non-small cell lung cancer, metastatic castrate-resistant prostate cancer, head and neck cancer, and gastric cancer.

About Accurins™

Accurins are BIND's targeted and programmable therapeutics, which are designed, utilizing BIND's medicinal nanoengineering platform, with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload. BIND has demonstrated in preclinical studies that Accurins can improve tumor growth suppression, achieve higher concentrations of the payload in tumors compared to the payload administered in conventional form, and have pharmacokinetics and tolerability differentiated from their therapeutic payloads.

####

About BIND Therapeutics
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND’s lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate resistant prostate cancer. To date in 2013, BIND has announced collaborations with Amgen, Inc., Pfizer Inc. and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines. BIND’s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women’s Hospital/Harvard Medical School of BIND’s scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad.

For more information, please click here

Contacts:
Media:
The Yates Network
Gina Nugent, 617-460-3579

Copyright © Business Wire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Bosch Sensortec launches ideation community to foster and accelerate innovative IoT applications : Creativity hub for customers, partners, developers and makers February 18th, 2019

Exotic spiraling electrons discovered by physicists: Rutgers-led research could lead to advances in lighting and solar cells February 18th, 2019

Tracking pollen with quantum dots: A pollination biologist from Stellenbosch University in South Africa is using quantum dots to track the fate of individual pollen grains. This is breaking new ground in a field of research that has been hampered by the lack of a universal method February 17th, 2019

Super-light, super-insulating ceramic aerogel keeps the hottest temperatures at bay February 17th, 2019

Govt.-Legislation/Regulation/Funding/Policy

NRL, AFRL develop direct-write quantum calligraphy in monolayer semiconductors February 15th, 2019

Researchers create ultra-lightweight ceramic material that withstands extreme temperatures: UCLA-led team develops highly durable aerogel that could ultimately be an upgrade for insulation on spacecraft February 15th, 2019

Sensitive sensor detects Down syndrome DNA February 14th, 2019

Laser-induced graphene gets tough, with help: Rice University lab combines conductive foam with other materials for capable new composites February 12th, 2019

Nanomedicine

Sensitive sensor detects Down syndrome DNA February 14th, 2019

Laser-induced graphene gets tough, with help: Rice University lab combines conductive foam with other materials for capable new composites February 12th, 2019

Nominations invited for $250,000 Kabiller Prize — the world’s largest monetary award for achievement in nanomedicine: An additional $10,000 award will honor a young investigator in nanoscience, nanomedicine February 7th, 2019

Kanazawa University research: Chirality inversion in a helical molecule at controlled speeds February 6th, 2019

Announcements

Bosch Sensortec launches ideation community to foster and accelerate innovative IoT applications : Creativity hub for customers, partners, developers and makers February 18th, 2019

Exotic spiraling electrons discovered by physicists: Rutgers-led research could lead to advances in lighting and solar cells February 18th, 2019

Tracking pollen with quantum dots: A pollination biologist from Stellenbosch University in South Africa is using quantum dots to track the fate of individual pollen grains. This is breaking new ground in a field of research that has been hampered by the lack of a universal method February 17th, 2019

Super-light, super-insulating ceramic aerogel keeps the hottest temperatures at bay February 17th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project